FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileABVC BioPharma, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ABVC
ABVC BioPharma, Inc. Stock AnalysisComprehensive stock analysis for ABVC BioPharma, Inc. (ABVC) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisABVC
ABVC
ABVC BioPharma, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ABVC
  1. Home
  2. Stocks
  3. ABVC BioPharma, Inc.

ABVC BioPharma, Inc.

🇺🇸ABVC•NASDAQ

ABVC BioPharma, Inc.

🇺🇸ABVC•NASDAQ
Market cap
$25.36M
Sentiment

Your view on ABVC

Mkt Cap
$25.36M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About ABVC BioPharma, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Uttam Yashwant Patil
Headquarters
44370 Old Warm Springs Boulevard, Fremont, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Uttam Yashwant Patil
Headquarters
44370 Old Warm Springs Boulevard, Fremont, CA, US
Description

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.

The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.

It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for ABVC BioPharma, Inc. from FRC's valuation model, read against the market price. ABVC last traded at $0.94; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for ABVC BioPharma, Inc.. Starting points for ABVC BioPharma, Inc.: EPS -$0.18, beta 0.50 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for ABVC BioPharma, Inc.. ABVC BioPharma, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for ABVC BioPharma, Inc.. Trailing twelve-month EPS for ABVC BioPharma, Inc. stands at -$0.18. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Analyst Ratings

Hold1 rating
  • Strong Buy0
  • Buy0
  • Hold1
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026
Avg. estimate-$0.40-$0.40$1.30
Low estimate-$0.40-$0.40$1.30
High estimate-$0.40-$0.40$1.30
No. of analysts111
Year-ago EPS-$0.121-$0.061-$0.391
Growth———

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026
Avg. estimate$113257.00$144441.00$35.28M
Low estimate$113257.00$144441.00$35.28M
High estimate$113257.00$144441.00$35.28M
No. of analysts111
Year-ago revenue-$795950.00$0.00$0.00
Growth+114.2%——
Recent analyst actions1 rating and price-target change, latest Nov 16, 2022 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for ABVC BioPharma, Inc.. ABVC BioPharma, Inc. has reported as a listed company since 2004. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ABVC17 companies · 8 funds
Compare ABVC with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ATNMActinium Pharmaceuticals, Inc.Biotechnology$47M
  • GRCEGrace Therapeutics, Inc.Biotechnology$28M
  • JUNSJupiter Neurosciences, Inc.Biotechnology$2M
  • LTRNLantern Pharma Inc.Biotechnology$6M
  • PDSBPDS Biotechnology CorporationBiotechnology$52M
  • RVPHReviva Pharmaceuticals Holdings, Inc.Biotechnology$36M

More Biotechnology companies

  • RNAAvidity Biosciences, Inc.NASDAQ$139M
  • RNACCartesian Therapeutics, Inc.NASDAQ$185M
  • RNAZTransCode Therapeutics, Inc.NASDAQ$1M
  • RNTXRein Therapeutics Inc.NASDAQ$35M
  • RNUGFReNeuron Group plcOTC$62,891
  • RNXTRenovoRx, Inc.NASDAQ$46M
  • ROIVRoivant Sciences Ltd.NASDAQ$28.0B
  • RVLPQRVL Pharmaceuticals plcOTC$1,114
  • RVMDRevolution Medicines, Inc.NASDAQ$36.1B
  • RVMDWRevolution Medicines, Inc. WarrantNASDAQ$34.1B
  • RVX.TOResverlogix Corp.TSX$26M

ETFs holding ABVC BioPharma, Inc.

% of the fund

  • VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
  • VXFVanguard Extended Market ETF$30.2B in assets0.00%
  • VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
  • VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets0.00%
  • VGRO.TOVanguard Growth ETF Portfolio$10.9B in assets0.00%
  • VBAL.TOVanguard Balanced ETF Portfolio$6.0B in assets
  • VUS.TOVanguard U.S. Total Market Index ETF (CAD-hedged)$1.4B in assets0.00%
  • VCNS.TOVanguard Conservative ETF Portfolio$977M in assets

Largest holders first, then the funds most concentrated in ABVC.

Open Comparable Analysis
Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by ABVC BioPharma, Inc. executives and directors. Shares of ABVC BioPharma, Inc. have traded between $0.40 and $5.48 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for ABVC BioPharma, Inc.. Coverage tracks ABVC BioPharma, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of ABVC BioPharma, Inc.

ABVC Analysis
Weak
Past1
Growth1
Health4
Profit1
Value1

News

Latest Market News